Lucid Diagnostics (LUCD) Stock Slips As Lofty P S Meets Heavy Losses
Lucid Diagnostics slipped about 2% today, a modest pullback for a stock that still trades at an expensive revenue multiple and sits under US$1. The move came as investors weighed another quarter of small revenue against heavy losses in this early stage cancer diagnostics story. The key issue is the contrast between a very high price to sales ratio and an income statement that remains deep in the red. Q2 revenue of roughly US$1.5 million and ongoing net losses kept the profitability gap firmly...
Lucid Diagnostics slipped about 2% today, a modest pullback for a stock that still trades at an expensive revenue multiple and sits under US$1. The move came as investors weighed another quarter of small revenue against heavy losses in this early stage cancer diagnostics story.
The key issue is the contrast between a very high price to sales ratio and an income statement that remains deep in the red. Q2 revenue of roughly US$1.5 million and ongoing net losses kept the profitability gap firmly...
What's Your Reaction?
